WO 2014/113634 Al 24 July 2014 (24.07.2014) P O P C T
Total Page:16
File Type:pdf, Size:1020Kb
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2014/113634 Al 24 July 2014 (24.07.2014) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/22 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/US20 14/0 11985 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 17 January 2014 (17.01 .2014) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/753,690 17 January 2013 (17.01.2013) U S kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: UNIVERSITY OF KANSAS [US/US]; 245 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Strong Hall, 1450 Jayhawk Boulevard, Lawrence, KS TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 66045 (US). EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (72) Inventors: SALUNKE, Deepak, B.; 245 Strong Hall, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 1450 Jayhawk Boulevard, Lawrence, KS 66045 (US). KM, ML, MR, NE, SN, TD, TG). GUO, Xiaoqiang; 245 Strong Hall, 1450 Jayhawk Boulevard, Lawrence, KS 66045 (US). DAVID, Sunil, A.; Published: 245 Strong Hall, 1450 Jayhawk Boulevard, Lawrence, KS — with international search report (Art. 21(3)) 66045 (US). — before the expiration of the time limit for amending the (74) Agent: ZACHARIADES, Nicholas, A.; Duane Morris claims and to be republished in the event of receipt of LLP, 5 100 Town Center Circle, Suite 650, Boca Raton, FL amendments (Rule 48.2(h)) 33486 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (54) Title: TOLL-LIKE RECEPTOR 2-AGONISTIC LIPOPEPTIDES, AND METHOD OF MAKING THE SAME FIG. (57) Abstract: The present disclosure is directed to a novel class of toll-like receptor 2-agnonistic (TLR2) lipopeptide compounds having specific structures, and synthetic methods of making the compounds. These compounds provide high potency of agonistic activities with human, other than murine, TLR2, and are useful as vaccine adjuvants. Vaccines are perhaps one of the most success - ful medical interventions against infectious disease. TOLL-LIKE RECEPTOR 2-AGONISTIC LIPOPEPTIDES, AND METHOD OF MAKING THE SAME CROSS-REFERENCE TO RELATED APPLICATIONS [001] The present application claims priority to US provisional application serial number 61/753,690 filed on January 17, 2013 which is incorporated herein by reference in its entirety. STATEMENT OF FEDERAL FUNDING [002] This invention was made with government support under federal contract number HHSN272200900033C, awarded by the National Institutes of Health. The government has certain rights in the invention. FIELD OF THE INVENTION [003] Embodiments are provided that are directed to synthetic methods for making toll-like receptor 2-agonistic (TLR2) lipopeptides, resulting compounds or compositions comprising TLR2 lipopeptides, and use of such compounds or compositions as vaccine adjuvants. BACKGROUND [004] Vaccines are perhaps one of the most successful medical interventions against infectious disease. An important component in the design of effective vaccines is the incorporation of appropriate immune potentiators (also termed adjuvants) along with the antigen; adjuvants initiate early innate immune responses, which lead to the induction of robust and long- lasting adaptive immune responses. More than eight decades have elapsed since the discovery of adjuvanticity of aluminum salts (primarily phosphate and hydroxide) and the repertoire of investigational adjuvants has grown to encompass a very wide range of materials; however, aluminum salt-based mineral salts (generically, and incorrectly, termed "alum") have, until the recent introduction of 3-0-desacyl-4'-monophosphoryl lipid A (MPL), remained the only adjuvants currently approved by the FDA. Aluminum salts have enjoyed a good safety record but are weak adjuvants for antibody induction, promoting a TH2-skewed, rather than a T 1 response. Furthermore, not only are aluminum salts ineffective at inducing cytotoxic T lymphocyte (CTL) or mucosal IgA antibody responses but also have an undesirable propensity to induce IgE isotype switching, which has been associated with allergic reactions in some subjects (Relyveld, E. H., et al. Vaccine 1998, 16, 1016-1023; Gupta, R. K. Adv. Drug Delivery Rev. 1998, 32, 155-172). [005] Toll-like receptors (TLRs) are pattern recognition receptors present on diverse cell types. TLRs recognize specific molecular patterns present in molecules that are broadly shared by pathogens but are sufficiently different so as to be distinguishable from host molecules and are collectively referred to as pathogen-associated molecular patterns (PAMPs). There are 10 TLRs in the human genome; these are transmembrane proteins with an extracellular domain having leucine-rich repeats (LRR) and a cytosolic domain called the ToU/IL-1 receptor (TIR) domain (Kumagai, Y. et al. J. Infect. Chemother. 2008, 14, 86-92). [006] The ligands for these receptors are highly conserved microbial molecules such as lipopolysaccharides (LPS) (recognized by TLR4), lipopeptides (TLR2 in combination with TLR1 or TLR6), flagellin (TLR5), single-stranded RNA (TLR7 and TLR8), double-stranded RNA (TLR3), CpG motif-containing DNA (recognized by TLR9), and profilin present on uropathogenic bacteria (TLR 11) (Kumagai, Y. et al J. Infect. Chemother. 2008, 14, 86-92; Takeda, K. Akira, S. Curr. Protoc. Immunol. 2007, Chapter 14, Unit 14, p 12). TLR1, -2, -4, -5, and -6 respond to extracellular stimuli, while TLR3, -7, -8, and -9 respond to intracytoplasmic PAMPs, being associated with the endolysosomal compartment (Kumagai, Y. et al. Infect. Chemother. 2008, 14, 86-92). The activation of TLRs by their cognate ligands leads to production of inflammatory cytokines, and up-regulation of MHC molecules and costimulatory signals in antigen-presenting cells as well as activating natural killer (NK) cells (innate immune response), in addition to priming and amplifying T- and B-cell effector functions (adaptive immune responses) (Akira, S. Adv. Immunol. 1902, 78, 1-56; Akira, S. et al. Nature Immunol. 2001, 2, 675-680; Cottalorda, A. et al. Eur. J. Immunol. 2006, 36, 1684-1693; Kaisho, T. et al. Biochim. Biophys. Acta 2002, 1589, 1-13). SUMMARY [007] This summary is provided to briefly indicate the nature and substance of the present disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. [008] Toll-like receptor (TLR) stimuli serve to link innate and adaptive immunity and can therefore be exploited as powerful adjuvants in eliciting both primary and anamnestic immune responses. Embodiments are directed to a novel class of compounds of toll-like receptor 2- agonistic (TLR2) lipopeptides, resulting compositions comprising such compounds, synthetic methods for making the compounds, and method of use of such compounds or compositions as vaccine adjuvants. [009] In some embodiments, the present disclosure provides a composition comprising a compound of general formula I : wherein: L is a functional group comprising: -C(0)-0-, -O-C(O)-, -C(O)-, -C(0)-NH-, -NH- C(O)-, -NH-C(0)-0-, -0-C(0)-NH-, alkyl, d -20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C4-20 heterocycle, C4-2oheteroaryl, C4-20 alkyl heterocycle, C -20 alkyl heteroaryl and Cj- 20 alkyoxyl, urea, esters, inverse esters, a keto group, amides, inverse amides, carbamate groups, inverse carbamate groups, wherein the Ci-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C4-2oheterocycle, C4-20 heteroaryl, C4-20 alkyl heterocycle, C -20 alkyl heteroaryl, Ci-20 alkyoxyl, and the -6 alkyl is unsubstituted or optionally substituted with a functional group comprising H, -OH, -OR' , -NH2, -NHR\ - R ' , -SH, -SR', -0-C(0)R', -C(0)R', -CF3, -OCF3, and an amino acid side chain, the -20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C -20 heterocycle, C4-20 heteroaryl, C4-2o alkyl heterocycle, C -20 alkyl heteroaryl, C^o alkyoxyl, and the - alkyl is optionally interrupted by one or more O, S, or N atoms, or one or more groups selected from cycloalkyl, -C(0)-0-, -O-C(O)-, -C(O)-, -C(0)-NH-, -NH-C(O)-, -NH-C(0)-0- and -0-C(0)-NH-, and R' is selected from radicals consisting of H, heteroaryl having 1 to 4 N, O and/or S atoms, -io alkyl, C2-io alkenyl, C2-10 alkynyl, C4-10 heterocycle and C - 10 heteroaryl; Ri is H or -5o alkyl, the Ci- 50 alkyl is unsubstituted or optionally substituted with a functional group selected from the group consisting of H, -OH, -OR', -NH2, -NHR', -NR' 2, -SH, -SR', -0-C(0)R', -C(0)R', -CF3, -OCF 3, an amino acid side chain or peptide fragment, where R' is selected from radicals consisting of H, heteroaryl having 1 to 4 N, O and/or S atoms, alkyl, C2- 0 alkenyl, C - o alkynyl, C -10 heterocycle and C4-10 heteroaryl; R2 is H, a natural or unnatural amino acid side chain, polar or non-polar groups and S- or R-enantiomers thereof.